-
06-09-2021, 10:29 AM
#2051
Originally Posted by percy
Off course the story keeps getting better.
"Our David" is the best story teller in the country.
Learnt his trade well at Methven.
Why do a one page presentation when "our David" can pad it out to over 50 pages.!.
And it really works.......................lol.
And the good story gets an additional chapter :
https://www.nzx.com/announcements/378586
Excerpt : "Comvita, global market leaders in Mānuka Honey, are delighted to announce a strategic partnership with Caravan, a Joint Venture with entertainment and sports agency, Creative Artists Agency (CAA).
Central to this partnership is the formation of a celebrity-backed lifestyle brand, using the natural healing properties of Mānuka Honey and Propolis for topical use."
Makes sound strategic sense to get more celebrity endorsements (free endorsements from Venus Williams & Novak Djokovic were great) as well as diversify market more into US & Europe.
-
06-09-2021, 11:18 AM
#2052
Sometimes it is interesting to look back in ones records.
Is it really already five years that Comvita signed this amazing MoU with China resources Ng Fung? Share Price at that stage above $10 and annual revenue (FY2016) of $202m;
https://www.nzx.com/announcements/291306
They talked at that stage (at the AGM) as well about doubling their revenue in 5 years (which would have been north of $400m in 2021). Talk is cheap, isn't it?
Well, we know how the story went. Annual revenue in 2021 actually was $192m (i.e. it did shrink, not rise over five years) and now it is the Americans who are supposed to pump the company fortunes up ... they must love these joint ventures ... just teach the Americans how they taught the Chinese ...
Lets hope this time is different, shall we :
Discl: I had recently a wee stake in Comvita, but sold out after the AGM, not convinced by the execution of their health strategy and didn't like their (Rest of - LOL) Asia strategy.
Anyway, good luck to holders.
Last edited by BlackPeter; 06-09-2021 at 11:19 AM.
----
"Prediction is very difficult, especially about the future" (Niels Bohr)
-
06-09-2021, 11:44 AM
#2053
Originally Posted by BlackPeter
Sometimes it is interesting to look back in ones records.
Is it really already five years that Comvita signed this amazing MoU with China resources Ng Fung? Share Price at that stage above $10 and annual revenue (FY2016) of $202m;
https://www.nzx.com/announcements/291306
They talked at that stage (at the AGM) as well about doubling their revenue in 5 years (which would have been north of $400m in 2021). Talk is cheap, isn't it?
Well, we know how the story went. Annual revenue in 2021 actually was $192m (i.e. it did shrink, not rise over five years) and now it is the Americans who are supposed to pump the company fortunes up ... they must love these joint ventures ... just teach the Americans how they taught the Chinese ...
Lets hope this time is different, shall we :
Discl: I had recently a wee stake in Comvita, but sold out after the AGM, not convinced by the execution of their health strategy and didn't like their (Rest of - LOL) Asia strategy.
Anyway, good luck to holders.
CVT really did one over on Ng Fung..? 2million shares at 10 bucks. Well done CVT
-
06-09-2021, 11:51 AM
#2054
Originally Posted by Rawz
CVT really did one over on Ng Fung..? 2million shares at 10 bucks. Well done CVT
I guess this is as well a way to see it. Question is - is it sustainable to sell overpriced shares promising the moon and the sun but delivering so little?
But hey - this used to be 5 years ago ... punters have short memories :
----
"Prediction is very difficult, especially about the future" (Niels Bohr)
-
06-09-2021, 11:59 AM
#2055
Originally Posted by Balance
And the good story gets an additional chapter :
https://www.nzx.com/announcements/378586
Excerpt : "Comvita, global market leaders in Mānuka Honey, are delighted to announce a strategic partnership with Caravan, a Joint Venture with entertainment and sports agency, Creative Artists Agency (CAA).
Central to this partnership is the formation of a celebrity-backed lifestyle brand, using the natural healing properties of Mānuka Honey and Propolis for topical use."
Makes sound strategic sense to get more celebrity endorsements (free endorsements from Venus Williams & Novak Djokovic were great) as well as diversify market more into US & Europe.
Ho hum, anything for an announcement. Has market been moved by this, up one cent.
-
11-10-2021, 02:41 PM
#2056
Solid Q1 performance despite lockdown, well one CVT. Can we get to $4...+
-
11-10-2021, 02:57 PM
#2057
Originally Posted by sb9
Solid Q1 performance despite lockdown, well one CVT. Can we get to $4...+
They said ‘strong’ …better than ‘solid’ eh
“ At the top of every bubble, everyone is convinced it's not yet a bubble.”
-
11-10-2021, 03:00 PM
#2058
Originally Posted by winner69
They said ‘strong’ …better than ‘solid’ eh
For sure, could've been another $4Mln more but for lockdown..
"This was despite $4m of goods scheduled for delivery in September being impacted by Covid related shipping delays (will be invoiced in October)."
-
11-10-2021, 03:09 PM
#2059
Originally Posted by sb9
For sure, could've been another $4Mln more but for lockdown..
"This was despite $4m of goods scheduled for delivery in September being impacted by Covid related shipping delays (will be invoiced in October)."
It's a bit confusing... the revenue includes the delayed shipments but the EBITDA doesnt?? Or does one assume the EBITDA growth does include the delayed shipments because the revenue does? Would they do that even though its not invoiced?
Not much growth in top line including the delayed shipments.. covid doing its best to slow them down.
This was despite $4m of goods scheduled for delivery in September being impacted by Covid related shipping delays (will be invoiced in October). Including these delayed shipments, revenue was improved by 4.5%.
-
11-10-2021, 03:15 PM
#2060
Originally Posted by Rawz
It's a bit confusing... the revenue includes the delayed shipments but the EBITDA doesnt?? Or does one assume the EBITDA growth does include the delayed shipments because the revenue does? Would they do that even though its not invoiced?
Not much growth in top line including the delayed shipments.. covid doing its best to slow them down.
I reckon ebitda doesn’t include the $4m sales not invoiced
The sales growth does include the $4m so at face value stuff all growth ……but is compared to a ‘strong pcp’
One thing …modest sales growth but strong ebitda growth means higher margins ….that’s good
Just need to be last years amazing 11/11 sales and it is really hunky dory
“ At the top of every bubble, everyone is convinced it's not yet a bubble.”
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks